You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 19, 2024

LAMISIL AT Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Lamisil At, and when can generic versions of Lamisil At launch?

Lamisil At is a drug marketed by Karo Hlthcare and is included in two NDAs.

The generic ingredient in LAMISIL AT is terbinafine hydrochloride. There are twenty-seven drug master file entries for this compound. Forty-one suppliers are listed for this compound. Additional details are available on the terbinafine hydrochloride profile page.

Drug patent expirations by year for LAMISIL AT
Drug Prices for LAMISIL AT

See drug prices for LAMISIL AT

Recent Clinical Trials for LAMISIL AT

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
The Malassezia FoundationEarly Phase 1
Oregon Health and Science UniversityEarly Phase 1
Pak Emirates Military HospitalPhase 3

See all LAMISIL AT clinical trials

US Patents and Regulatory Information for LAMISIL AT

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Karo Hlthcare LAMISIL AT terbinafine GEL;TOPICAL 021958-001 Jul 24, 2006 OTC Yes Yes ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Karo Hlthcare LAMISIL AT terbinafine hydrochloride SOLUTION;TOPICAL 021124-001 Mar 17, 2000 OTC Yes Yes ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Karo Hlthcare LAMISIL AT terbinafine hydrochloride SPRAY;TOPICAL 021124-002 Mar 17, 2000 OTC Yes Yes ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for LAMISIL AT

International Patents for LAMISIL AT

See the table below for patents covering LAMISIL AT around the world.

Country Patent Number Title Estimated Expiration
Germany 2862103 ⤷  Try a Trial
Czech Republic 283019 Topická farmaceutická kompozice, způsob její přípravy a způsob léčení fungálních infekcí (TOPIC PHARMACEUTICAL COMPOSITION) ⤷  Try a Trial
Japan H0149690 ⤷  Try a Trial
Philippines 22166 PROPENYLAMINES, METHOD OF USE, PHARMACEUTICAL COMPOSITION CONTAINING THEM ⤷  Try a Trial
Finland 782446 ⤷  Try a Trial
Portugal 68448 ⤷  Try a Trial
Italy 1260710 COMPOSIZIONI FARMACEUTICHE CONTENENTI UN COMPOSTO ALLILAMMINICO QUALE PRINCIPIO ATTIVO. ⤷  Try a Trial
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for LAMISIL AT

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0024587 93C0136 Belgium ⤷  Try a Trial PRODUCT NAME: TERBINAFINE (250 MG) SOUS FORME DE CHLORHYDRATE (281,25 MG); NAT. REG.: 616 S 201 F3 19911031; FIRST REG.: GB PL 0101/0304 19901003
0024587 SPC/GB93/096 United Kingdom ⤷  Try a Trial SPC/GB93/096, EXPIRES: 20050805
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.